select trial semaglutide cardiovascular outcomes non-diabetic 2023 Population‐level impact of 2.4 mg in patients with obesity or overweight and disease: A modelling study based on the - Nanna - 2025 - Diabetes, Obesity and Metabolism VisualAbstract: Semaglutide and Cardiovascular Outcomes

Some people have penile curvature at birth (congenital penile curvature or chordee)

However, patients with diabetes or a history of low blood sugar should be especially cautious

Several practical factors may explain fatigue during GLP-1 therapy: Reduced food intake due to appetite suppression can lead to lower energy consumption Gastrointestinal side effects like nausea can be physically draining Adaptation to metabolic changes as your body adjusts to the medication For people with diabetes who take insulin or sulfonylureas (like gliclazide) alongside GLP-1 medications, low blood glucose (hypoglycaemia) may cause fatigue

Insulin resistance shares many of the same symptoms of AFS, and both conditions may aggravate each other